These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35538760)

  • 21. Investigation on the mechanism of Ginkgo Folium in the treatment of Non-alcoholic Fatty Liver Disease by strategy of network pharmacology and molecular docking.
    Sun Y; Wang L; Du L; Yu H; Tian Y; Jin H; Li S; Yan S; Xiao X
    Technol Health Care; 2023; 31(S1):209-221. PubMed ID: 37038793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the Protective Effects and Mechanism of Huaji Jianpi Decoction against Nonalcoholic Fatty Liver Disease by Network Pharmacology and Experimental Validation.
    Xue H; Wang Y; Xiang H; Song Q; Zhang G; Wang J; Ge S
    Evid Based Complement Alternat Med; 2022; 2022():5440347. PubMed ID: 36199550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research on the Mechanism of Qushi Huayu Decoction in the Intervention of Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Molecular Docking Technology.
    Gao SS; Sun JJ; Wang X; Hu YY; Feng Q; Gou XJ
    Biomed Res Int; 2020; 2020():1704960. PubMed ID: 33204683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease.
    Yu DD; Van Citters G; Li H; Stoltz BM; Forman BM
    Bioorg Med Chem; 2021 Jul; 41():116193. PubMed ID: 34022528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
    Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
    Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Network pharmacology analysis of Chaihu Lizhong Tang treating non-alcoholic fatty liver disease.
    Zhang M; Yuan Y; Zhou W; Qin Y; Xu K; Men J; Lin M
    Comput Biol Chem; 2020 Jun; 86():107248. PubMed ID: 32208163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Study on the Therapeutic Efficacy of San Zi Yang Qin Decoction for Non-Alcoholic Fatty Liver Disease and the Underlying Mechanism Based on Network Pharmacology.
    Li Y; Liu Y; Yang M; Wang Q; Zheng Y; Xu J; Zheng P; Song H
    Evid Based Complement Alternat Med; 2021; 2021():8819245. PubMed ID: 33505505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating network pharmacology and in vivo experimental validation to reveal the alleviation of mailuoning oral liquid on non-alcoholic fatty liver disease.
    Jia W; Wang K; Zhang S; Lu W; Du A; Li J; Ji L; Xu H
    Phytomedicine; 2022 Sep; 104():154326. PubMed ID: 35853303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uncovering the protective mechanism of baicalin in treatment of fatty liver based on network pharmacology and cell model of NAFLD.
    Wen Y; Yi F; Zhang J; Wang Y; Zhao C; Zhao B; Wang J
    Int Immunopharmacol; 2024 Nov; 141():112954. PubMed ID: 39153306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Ganshuang granules on non-alcoholic fatty liver and underlying mechanism: a network pharmacology and experimental verification.
    Guoguo Z; Bingjie S; Tianyan Z; Shaoxiu JI; Jingwei LI; Yanni D; Feng L; Dong W
    J Tradit Chin Med; 2024 Feb; 44(1):122-130. PubMed ID: 38213247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanism of Ginkgo biloba in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease based on network pharmacology, molecular docking, and experimental evaluations.
    Xu S; Tang L; Qian X; Wang Y; Gong J; Yang H; Su D
    J Food Biochem; 2022 Dec; 46(12):e14419. PubMed ID: 36121703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation.
    Sun B; Jia Y; Hong J; Sun Q; Gao S; Hu Y; Zhao N; Zhao R
    J Agric Food Chem; 2018 Jul; 66(29):7633-7642. PubMed ID: 29961332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanism of Alisma orientale in treating nonalcoholic fatty liver disease].
    Jiang-Dong D; Chuan-Yan L; Bing Y; Yue W; Li C; Liang F; Xiao-Bin J
    Zhongguo Zhong Yao Za Zhi; 2020 Sep; 45(17):4140-4148. PubMed ID: 33164398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
    Zhou C; Zhou J; Han N; Liu Z; Xiao B; Yin J
    Int Immunopharmacol; 2015 Mar; 25(1):218-28. PubMed ID: 25661699
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Peng C; Li J; Ke X; Liu F; Huang KE
    Ann Med; 2023 Dec; 55(1):2200258. PubMed ID: 37096878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radix Polygoni Multiflori and Its Main Component Emodin Attenuate Non-Alcoholic Fatty Liver Disease in Zebrafish by Regulation of AMPK Signaling Pathway.
    Yu L; Gong L; Wang C; Hu N; Tang Y; Zheng L; Dai X; Li Y
    Drug Des Devel Ther; 2020; 14():1493-1506. PubMed ID: 32346285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
    Zhang J; Du H; Shen M; Zhao Z; Ye X
    J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro.
    Chen J; Liu J; Wang Y; Hu X; Zhou F; Hu Y; Yuan Y; Xu Y
    Biomed Pharmacother; 2017 Jul; 91():621-631. PubMed ID: 28486193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
    Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
    Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Huanglian-Hongqu herb pair improves nonalcoholic fatty liver disease via NF-κB/NLRP3 pathway in mice: network pharmacology, molecular docking and experimental validation.
    Wang Z; Qiu H; Yang Y; Zhang Y; Mou T; Zhang X; Zhang Y
    Hereditas; 2024 Apr; 161(1):12. PubMed ID: 38566171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.